Entering text into the input field will update the search result below

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Jul. 06, 2022 9:38 AM ETEvoke Pharma, Inc. (EVOK)By: Ravikash, SA News Editor

IP, Intellectual Property Patent Concept

Olivier Le Moal

  • Evoke Pharma (NASDAQ:EVOK) said the Canadian Intellectual Property Office granted a patent covering methods of use for nasal delivery of Gimoti's formulation, metoclopramide, to treat diabetic gastroparesis (DG).
  • The patent titled “Nasal Formulations of Metoclopramide" expires in 2029, according to the company's July 6 press release.
  • Evoke said the new patent corresponds to the two other U.S. patents under the same title that expire in 2029 and 2030, respectively.
  • DG is a stomach problem related to diabetes which causes delayed gastric emptying.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.